Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31316 | 1.00 | HSD11B1 (0.43) | HSD11B1KMT2AALDH1A1HSP90AA1P2RY2 | |
| SCHEMBL14141983 | 1.00 | HSD11B1 (0.43) | HSD11B1KMT2AALDH1A1HSP90AA1P2RY2 | |
| SCHEMBL5120356 | 1.00 | HSD11B1 (0.43) | HSD11B1KMT2AALDH1A1HSP90AA1P2RY2 | |
| SCHEMBL23524 | 0.87 | KMT2A (0.44) | KMT2AALDH1A1HSP90AA1P2RY2GPR17 | |
| SCHEMBL29993001 | 0.87 | KMT2A (0.44) | KMT2AALDH1A1HSP90AA1P2RY2GPR17 | |
| SCHEMBL14141639 | 0.87 | KMT2A (0.44) | KMT2AALDH1A1HSP90AA1P2RY2GPR17 | |
| SCHEMBL5672285 | 0.87 | TDP1 (0.40) | HSD11B1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL7495927 | 0.87 | TDP1 (0.40) | HSD11B1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL7490542 | 0.85 | TDP1 (0.43) | HSD11B1KMT2AALDH1A1LMNASLC1A3 | |
| SCHEMBL5671784 | 0.85 | TDP1 (0.43) | HSD11B1KMT2AALDH1A1LMNASLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613783-B1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LTD (IN) | 2019-06-12 | — | — | EP | disclosed |
| WO-2013001544-A9 | ANTI-THROMBOTIC COMPOUNDS | IPCA LABORATORIES LIMITED (IN) | 2014-09-12 | — | — | WO | disclosed |
| EP-2675813-A1 | ANTI-THROMBOTIC COMPOUNDS | IPCA Laboratories Limited (IN) | 2013-12-25 | — | — | EP | disclosed |
| US-20130316987-A1 | Anti-Thrombotic Compounds | IPCA LABORATORIES LIMITED (IN) | 2013-11-28 | — | — | US | disclosed |
| US-20130316986-A1 | Anti-Thrombotic Compounds | IPCA LABORATORIES LIMITED (IN) | 2013-11-28 | — | — | US | disclosed |
| EP-2613783-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA Laboratories Limited (IN) | 2013-07-17 | — | — | EP | disclosed |
| WO-2013001544-A1 | ANTI-THROMBOTIC COMPOUNDS | IPCA LABORATORIES LIMITED (IN) | 2013-01-03 | — | — | WO | disclosed |
| EP-2540729-A1 | (7aS, 2'S)-2-Oxoclopidogrel as anti-thrombotic compound | IPCA Laboratories Limited (IN) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012025942-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LIMITED (IN) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130316987-A1 | Anti-Thrombotic Compounds | TBXA2R, SERPINC1, F2 | HSD11B1 2012/4885KMT2A 4761/4885ALDH1A1 3034/4885 |
| US-20130316986-A1 | Anti-Thrombotic Compounds | TBXA2R, SERPINC1, F2 | HSD11B1 2012/4885KMT2A 4761/4885ALDH1A1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.